Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of TPI1 As a potential therapeutic target in pancreatic cancer with dependency of TP53 mutation using multi-omics analysis.

Cancer science - 1 Nov 2024

Toyoda Tomoaki, Miura Nami, Kato Shingo, Masuda Takeshi, Ohashi Ryuji, Matsushita Akira, Matsuda Fumio, Ohtsuki Sumio, Katakura Akira, Honda Kazufumi

Abstract excerpt

Mutations of KRAS, CDKN2A, TP53, and SMAD4 are the four major driver genes for pancreatic ductal adenocarcinoma (PDAC), of which mutations of KRAS and TP53 are the most frequently recognized. However, molecular-targeted therapies for mutations of KRAS and TP53 have not yet been developed. To identify novel molecular targets, we newly established organoids with the Kras mutation (KrasmuOR) and Trp53 loss of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Pancreatic Ductal
Share to Glycolysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Metabolomics

Share to Molecular Targeted Therapy

Share to Multiomics

Share to Organoids

Share to Proteomics

Share to Triose-Phosphate Isomerase

Source

Open in PubMed Open full text

Identifiers

PMID: 39259678
DOI: 10.1111/cas.16302
PMCID: PMC11531968

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of TPI1 As a potential therapeutic target in pancreatic cancer with dependency of TP53 mutation using multi-omics analysis.PMID 39259678Read ↗

Interplays of glucose metabolism and KRAS mutation in pancreatic ductal adenocarcinoma.Semantic proximity Read ↗

Metabolic reprogramming by driver mutation-tumor microenvironment interplay in pancreatic cancer: new therapeutic targets.Semantic proximity Read ↗

Pancreatic Cancer Research beyond DNA Mutations.Semantic proximity Read ↗

Mutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma.Semantic proximity Read ↗

[A Review of Metabolic Stress and Development of Pancreatic Cancer].Semantic proximity Read ↗

Genome-wide CRISPR screens identify PKMYT1 as a therapeutic target in pancreatic ductal adenocarcinomaSemantic proximity Read ↗

The biological role of metabolic reprogramming in pancreatic cancerSemantic proximity Read ↗

The Mutant p53-Driven Secretome Has Oncogenic Functions in Pancreatic Ductal Adenocarcinoma Cells.Semantic proximity Read ↗

Single-Cell Analysis Differentiates the Effects of p53 Mutation and p53 Loss on Cell Compositions of Oncogenic Kras-Driven Pancreatic Cancer.Semantic proximity Read ↗

The complex landscape of pancreatic cancer metabolismSemantic proximity Read ↗

Lipidome atlas of p53 mutant variants in pancreatic cancer.Semantic proximity Read ↗

Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.